Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29857805 | 1.00 | HTR2A (0.39) | HTR2ASLC6A4KCNH2P2RX7PSEN1 | |
| SCHEMBL29673143 | 0.83 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2P2RX7PSEN1 | |
| SCHEMBL16961564 | 0.83 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2P2RX7PSEN1 | |
| SCHEMBL30303054 | 0.82 | ALDH1A1 (0.43) | P2RX7ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL697564 | 0.82 | ALDH1A1 (0.43) | P2RX7ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL16955926 | 0.79 | CA2 (0.39) | HTR2ASLC6A4KCNH2P2RX7PSEN1 | |
| SCHEMBL18584769 | 0.79 | ESR2 (0.50) | ALDH1A1MAPTCYP3A4CA9 | |
| SCHEMBL2370502 | 0.79 | SLC6A4 (0.40) | HTR2ASLC6A4KCNH2P2RX7PSEN1 | |
| SCHEMBL31085527 | 0.78 | IDO1 (0.40) | SLC6A4ALDH1A1KDM4ECYP1A2CA3 | |
| SCHEMBL3309883 | 0.78 | IDO1 (0.40) | SLC6A4ALDH1A1KDM4ECYP1A2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119954810-A | Regulator of fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119947718-A | Tricyclic aryl derivatives, and compositions and methods thereof | 昂胜医疗科技公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118302427-A | Fused ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| CN-112010860-B | Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof | 南京纳丁菲医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-0212428-B1 | DIHYDROBENZO/B /THIOPHENES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS ANTIFUNGALS | SCHERING CORPORATION (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4731364-A | Dihydrobenzo(B)thiophenes and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0212428-A1 | Dihydrobenzo/b /thiophenes and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | HTR2A 4646/4885SLC6A4 4037/4885KCNH2 4591/4885 |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | HTR2A 2649/4885SLC6A4 361/4885KCNH2 4352/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | HTR2A 4616/4885SLC6A4 3194/4885KCNH2 3761/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | HTR2A 4250/4885SLC6A4 4836/4885KCNH2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.